Global Teams Get $125M to Tackle Cancer’s Toughest Mysteries

BOSTON, MA – March 04, 2026 – In a significant move to push the boundaries of cancer science, the Cancer Grand Challenges initiative today announced a $125 million investment distributed among five new international research teams. Each team will receive up to $25 million over five years to pursue some of the most complex and unanswered questions in cancer research. This major funding round, co-led by Cancer Research UK and the US National Cancer Institute (NCI), matches a previous record for the initiative and brings its total investment to $624 million since 2016.

The newly funded projects are anything but conventional. They aim to explore radical new territories, from understanding why some people seem naturally immune to cancer, to deciphering the hidden language between the brain and tumors, and even forcing cancer cells to self-destruct. This commitment underscores a global shift towards funding high-risk, high-reward science that has the potential to fundamentally alter our approach to preventing, diagnosing, and treating this devastating disease.

A New Model for Moonshot Research

The Cancer Grand Challenges initiative was founded on the principle that some scientific obstacles are too large for any single researcher, institution, or even country to overcome alone. It operates on a model that starkly contrasts with traditional, more conservative research grants, which often favor incremental advances over transformative leaps. By identifying a set of “grand challenges” and inviting the world’s brightest minds to form interdisciplinary super-teams, the program actively encourages audacious ideas that might otherwise be deemed too risky for conventional funding streams.

“These new global teams of scientists are tackling questions many would consider too difficult or too ambitious,” said Dr. Judy Garber, Vice-Chair of the Cancer Grand Challenges Scientific Committee. “By bringing together expertise from across the cancer research space, Cancer Grand Challenges is enabling the kind of collaborative science that has the potential to address these truly ‘grand challenges’ and to actually to change how we prevent, detect and treat cancer worldwide.”

This approach has already begun to yield significant insights. Past teams funded by the initiative have reshaped our understanding of how genetic mutations drive cancer, developed cutting-edge tools for mapping tumors in three dimensions, and uncovered the complex role of the microbiome in colorectal cancer. The long-term, substantial funding allows researchers the freedom to pursue complex, multi-year projects without the constant pressure of short-term grant cycles.

Dr. David Scott, Director of Cancer Grand Challenges, highlighted the importance of this unique structure. “Achieving impact at this scale is only possible because of the commitment of our co-founders... and our coalition of visionary funding partners,” he stated. “Their support enables truly bold, high-risk science that wouldn’t be possible through traditional funding routes.”

The Five New Frontiers of Cancer Science

The five newly funded teams will direct their efforts toward distinct but equally ambitious goals, each representing a major gap in our current knowledge.

• The CAUSE Team: Led by Dr. Ludmil Alexandrov at the University of California San Diego, this team will investigate the hidden origins of cancer. While we know DNA mutations are the root cause, many of these genetic alterations have no known source. The CAUSE team will develop new technologies to hunt for the elusive chemical fingerprints left on DNA by environmental exposures or internal bodily processes, aiming to uncover the secret drivers of colorectal, kidney, and liver cancers and create powerful new tools for prevention.

• The ATLAS Team: Why do some heavy smokers or individuals with strong genetic predispositions never develop cancer? The ATLAS team, led by Dr. Paul Bastard at Institut Imagine in Paris, will study these “cancer-proof” individuals, including centenarians who have remained cancer-free. Their hypothesis is that these people may possess unique autoantibodies that help their immune systems recognize and eliminate cancer cells at the earliest stage. By mapping these protective antibody patterns, they hope to develop novel strategies for cancer prevention and early detection.

• The InteroCANCEption Team: Headed by Dr. Leanne Li at the Francis Crick Institute, this team is venturing into the fascinating field of neuro-oncology. They will explore “interoception”—the brain’s ability to sense and regulate the body’s internal state—to understand how the nervous system communicates with tumors. By mapping the nerve pathways between the brain and cancers of the lung, pancreas, and colon, they aim to discover whether manipulating these signals with drugs or even neural implants could become a new form of cancer treatment.

• The REWIRE-CAN Team: Rather than trying to inhibit cancer growth, this team plans to push cancer cells into overdrive until they self-destruct. Led by Professor Bart Vanhaesebroeck of University College London, the REWIRE-CAN team will explore ways to hyperactivate growth signals within cancer cells, causing them to become fatally stressed. Their focus will be on colorectal cancer, a disease where treatment resistance is a major hurdle and incidence among younger adults is alarmingly on the rise. They hope this “rewiring” strategy can reprogram even the most stubborn tumors to become vulnerable to treatment again.

• The ILLUMINE Team: The human genome contains vast, uncharted territories. The ILLUMINE team, led by Professor Reuven Agami of the Netherlands Cancer Institute, will venture into the “dark proteome”—the vast collection of proteins whose functions are completely unknown. Many of these mysterious proteins may play a critical role in some of the deadliest cancers, including brain, pancreatic, and ovarian tumors. The team’s goal is to identify which of these “dark proteins” are involved in cancer and whether they can be used as new targets for next-generation immunotherapies.

A Global Alliance Forged for Impact

This $125 million investment is not just about the science; it's about the power of global collaboration. The five new teams bring together 42 new senior investigators from 34 institutions across nine countries, expanding the Cancer Grand Challenges community to more than 1,800 researchers worldwide. This network is designed to break down the silos that often hinder scientific progress, uniting experts from fields as diverse as genomics, neuroscience, immunology, and computational biology.

“Solving cancer’s toughest problems requires scientific courage and collaboration,” noted Dr. Dinah Singer, Deputy Director of the US National Cancer Institute. “Through Cancer Grand Challenges, we are empowering teams to pursue innovative ideas that may reshape our understanding of how cancer begins, evolves and responds to treatment.”

The funding itself is a collaborative effort, sourced from a coalition of international partners including the Bowelbabe Fund for Cancer Research UK, the Cancer Research Institute, the Dutch KWF Cancer Society, and others. This diverse group of philanthropic organizations and venture firms reflects a shared belief that pooling resources is essential to tackling challenges of this magnitude.

Over the next five years, these teams will not only conduct their groundbreaking research but are also mandated to share their data and findings widely, ensuring that any progress benefits the entire scientific community. Their work represents a calculated gamble on the idea that by asking the biggest questions and giving brilliant minds the freedom to explore, we can achieve breakthroughs that were once considered impossible.